Deoxytubulosine : Nucleotide Synthesis Disrupter, Antileukemic Alkaloid, Traditional Chemotype

Deoxytubulosine is a rare β-carboline-benzoquinolizidine alkaloid from traditional Indian medicine, wielding potent dual inhibition of thymidylate synthase and dihydrofolate reductase; a key enzymes in cancer cell proliferation and DNA synthesis.

---

1. Overview:

Deoxytubulosine is a complex, plant-derived isoquinoline alkaloid belonging to the emetine class. It functions as a potent inhibitor of thymidylate synthase (TS) and dihydrofolate reductase (DHFR), two essential enzymes in the de novo synthesis of DNA precursors. Its mechanism of action positions it as a promising, naturally derived antileukemic and antitumor agent, primarily investigated for hematological malignancies.

2. Origin & Common Forms:

A specialized metabolite first isolated from the roots and fruits of Alangium lamarckii (also known as Alangium salvifolium), a plant used in Indian traditional medicine . It is not a consumer supplement; available exclusively as a high-purity research chemical.

3. Common Supplemental Forms: Standard & Enhanced

· Research-Grade Reference Standard: The only available form. Typically provided as a crystalline powder (purity >98%) for laboratory use in cancer biology, enzymology, and drug discovery .

· No supplemental or "enhanced" consumer forms exist due to its potent cytotoxicity and lack of human safety data.

4. Natural Origin:

· Sources: Isolated primarily from the dried fruits and root bark of Alangium lamarckii Thwaites (Cornaceae), and also found in Alangium salvifolium and Tylophora hirsuta .

· Precursors: Biosynthesized in the plant through the condensation of secologanin (from the iridoid pathway) with dopamine/tryptamine derivatives, placing it in the emetine alkaloid family.

5. Synthetic / Man-made:

· Process: While full chemical synthesis is theoretically possible, commercial production is not synthetic. Research quantities are obtained via extraction and multi-step chromatographic purification from plant biomass .

6. Commercial Production:

· Precursors: Harvested, dried, and powdered Alangium fruits or roots.

· Process: Involves methanol or ethanol extraction, acid-base partitioning, column chromatography (silica gel, Sephadex), and preparative HPLC to isolate the pure compound.

· Purity & Efficacy: High-performance liquid chromatography (HPLC) and mass spectrometry are used to verify purity >98%. "Efficacy" is measured by its IC50 against target enzymes (e.g., TS) or cancer cell lines.

7. Key Considerations:

A Lead Molecule, Not a Medicine. Deoxytubulosine is a powerful research tool and a potential pharmacophore for anticancer drug development. Its potent, irreversible inhibition of thymidylate synthase, combined with its natural origin, makes it a valuable scaffold. It is not for human consumption and remains in preclinical investigation.

8. Structural Similarity:

A β-carboline-benzoquinolizidine alkaloid. Structurally related to tubulosine and emetine. It features a complex tetracyclic system with four chiral centers, a tetrahydro-β-carboline moiety linked to a benzoquinolizidine core .

9. Biofriendliness:

· Utilization: In research models, it is cell-permeable and reaches intracellular targets.

· Metabolism & Excretion: Human data is non-existent. Preclinical evidence suggests tight, potentially irreversible binding to its target enzymes .

· Toxicity: Exhibits potent cytotoxicity. Its mechanism—disrupting DNA synthesis—is inherently toxic to rapidly dividing cells, conferring a narrow therapeutic index.

10. Known Benefits (Clinically Supported):

No direct human clinical benefits are established. Supported benefits are from robust preclinical research:

· Inhibition of Thymidylate Synthase (TS): Potently inhibits TS (IC50 = 40-50 µM), a key enzyme elevated in leukemias, suggesting potential as an antileukemic agent .

· Cytotoxicity Against Cancer Cell Lines: Shows cytotoxic effects against human lung carcinoma (A-549), breast carcinoma (MCF-7), and Dalton's ascitic lymphoma cells .

· Dihydrofolate Reductase (DHFR) Inhibition: Also inhibits DHFR (IC50 ≈ 30 µM), disrupting nucleotide biosynthesis through dual mechanisms .

11. Purported Mechanisms:

· Thymidylate Synthase Inhibition: Directly inhibits TS, blocking the conversion of dUMP to dTMP—a rate-limiting step in DNA synthesis. Inhibition appears to be noncompetitive and tight-binding .

· DHFR Inhibition: Inhibits dihydrofolate reductase, disrupting tetrahydrofolate recycling and further starving the cell of thymidine precursors.

· DNA Binding: Exhibits strong binding affinity to DNA, which may contribute to its cytotoxic effects independently of enzyme inhibition .

· Enzyme Target Docking: Computational studies show high binding affinity for glucosidase and GLP1 targets, suggesting possible metabolic applications .

12. Other Possible Benefits Under Research:

· Antidiabetic Potential: Identified in network pharmacology studies as a potential antidiabetic agent, with binding affinity to alpha-glucosidase targets .

· Antileukemic Activity: Specifically studied for chronic myeloblastic leukemia (CML) and acute lymphoblastic leukemia (ALL), where TS levels are elevated up to 66-fold .

· Structure-Activity Relationship Studies: Serves as a scaffold for designing novel anticancer agents with improved potency and selectivity.

13. Side Effects:

Based on preclinical toxicology:

· Major Toxicity: Potent cytotoxicity to rapidly dividing cells (bone marrow, gastrointestinal epithelium) is predicted. This is the desired on-target effect for cancer but causes significant toxicity in non-tumor tissues.

· No human safety data exists. Not for human ingestion.

14. Dosing & How to Take:

There is no established safe dose for human consumption. Research applications use:

· In vitro cell culture: Typically 1-50 µM concentrations .

· Enzyme assays: IC50 values at 40-50 µM for TS inhibition .

· Not for human ingestion.

15. Tips to Optimize Benefits:

Not applicable for human use. For research:

· Target Selection: Most relevant for leukemia research due to elevated TS expression in these malignancies .

· Combination Studies: May synergize with other antimetabolites (e.g., 5-fluorouracil, methotrexate) that target the folate pathway.

16. Not to Exceed / Warning / Interactions:

· CRITICAL WARNING: Not for human consumption. Purely a research chemical.

· Drug Interactions (Research Context): Its mechanism overlaps with classic antifolates (methotrexate) and TS inhibitors (5-fluorouracil). Combined use in experimental models would require careful design.

· Medical Conditions: No human indications.

17. LD50 & Safety:

· Acute Toxicity (LD50): Not formally established. High cytotoxicity profile suggests significant toxicity at low doses.

· Human Safety: No clinical trial data. Its potent mechanism of action classifies it as a hazardous compound requiring laboratory containment.

18. Consumer Guidance:

· Label Literacy: Will be labeled explicitly as a "Research Chemical," "Reference Standard," or "For Laboratory Use Only." CAS Number: 2632-30-6 .

· Quality Assurance: Researchers must source from reputable biochemical suppliers (e.g., Benchchem, EvitaChem) that provide Certificates of Analysis (CoA) with HPLC purity verification .

· Manage Expectations: This is a potent natural product with significant therapeutic potential but equally significant toxicity. Its future lies in medicinal chemistry optimization and drug development, not in direct supplementation.

---

Note: Deoxytubulosine is one of several emetine-type alkaloids found in Alangium species, alongside tubulosine, cephaeline, and psychotrine . Its close structural relative, tubulosine, has been more extensively studied, but deoxytubulosine's distinct TS inhibition profile makes it uniquely valuable as a biochemical tool.